Rona Therapeutics Licenses ALK7 RNAi Therapy to Roche
Rona Therapeutics entered a global license agreement with Roche for an ALK7-targeting RNAi therapy for obesity and metabolic diseases.
Rona Therapeutics has signed a global license agreement with Roche covering an RNAi therapy targeting ALK7 for obesity and metabolic diseases.